Company Overview
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
Why Investors Should Care
Net profit has compounded at 40.9% per year over the last five years.
Revenue has grown at a 28.5% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.14.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $1.40B (+17.5% YoY); net profit $177.69M.
- Trailing 12 Months Year-on-year growth — revenue +14.9%, earnings -23.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 28.5%, profit CAGR 40.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 28.52% |
| 1 Year: | 14.90% |
Compounded Profit Growth
| 5 Years: | 40.87% |
| 1 Year: | -23.50% |
Stock Price Performance
| 1 Year: | +24.04% |
| 6 Months: | -5.99% |
| 3 Months: | -0.25% |
| 1 Month: | -1.66% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)39.60 · Neutral
P/E of 78.25 is above the sector median of 24.83 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 28.5% over 5 years.
- Profit CAGR of 40.9% over 5 years.
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 78.2.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PEN Penumbra, Inc. R3KPHARMA | 319.26 | 78.25 | $12.58B | 0.00% | 11.52% | 11.37% | 28.52% | 40.87% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 73.21M | 80.59M | 83.91M | - | 102.70M | 109.64M | 111.81M | - | 128.44M | 134.20M | 139.50M | - | 137.33M | 105.11M | 151.08M | - | 169.20M | 184.26M | 190.12M | - | 203.90M | 208.34M | 213.68M | - | 241.40M | 261.50M | 270.95M | - | 278.65M | 299.40M | 301.04M | - | 324.14M | 339.45M | 354.69M | 385.38M | 374.76M | 390.05M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 115.44M | 114.27M | 123.26M | 121.35M | 125.10M |
| Gross Profit | 42.87M | 46.58M | 47.71M | 50.93M | 54.78M | 63.73M | 66.56M | 72.25M | 75.01M | 78.71M | 83.91M | 93.93M | 96.00M | 98.13M | 88.01M | 64.93M | 90.92M | 94.31M | 111.34M | 118.69M | 119.91M | 125.45M | 127.42M | 134.03M | 135.33M | 138.43M | 151.07M | 166.86M | 177.72M | 186.99M | 181.14M | 162.83M | 200.31M | - | 215.88M | 224.01M | 240.42M | 262.13M | 253.41M | 264.94M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 183.18M | 191.58M | 202.90M | 215.18M | 223.91M |
| Operating Income | -1.36M | - | -2.05M | -1.33M | 683.00K | - | 4.04M | 9.28M | -20.85M | - | 11.15M | 12.80M | 12.98M | - | 610.00K | -17.65M | -20.16M | - | 13.46M | 10.31M | 8.78M | - | -4.05M | -139.00K | 5.43M | - | 8.01M | 17.89M | 12.62M | - | 12.10M | -80.96M | 35.36M | - | 40.35M | 40.83M | 48.84M | 59.23M | 38.23M | 41.04M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 51.14M | 55.15M | 68.43M | 46.58M | 52.11M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 319.00K | 338.00K | 333.00K | 317.00K | 311.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 45.31M | 52.33M | 63.63M | 41.69M | 46.19M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 40.00K | 6.47M | 16.29M | 9.10M | 11.38M |
| Net Income | 11.91M | -2.40M | -3.11M | -1.56M | 238.00K | 9.08M | 5.49M | 13.38M | -18.93M | 6.66M | 10.70M | 16.59M | 11.48M | 9.69M | 1.43M | -11.96M | -8.81M | 3.65M | 11.84M | 9.23M | 8.85M | -24.63M | 79.00K | -3.69M | -2.27M | 3.88M | 8.56M | 18.96M | 9.21M | 54.22M | 11.00M | -60.20M | 29.53M | - | 39.22M | 45.27M | 45.85M | 47.34M | 32.58M | 34.81M |
| Diluted EPS | 0.35 | -0.08 | -0.10 | -0.05 | 0.01 | 0.25 | 0.15 | 0.37 | -0.55 | 0.18 | 0.30 | 0.46 | 0.32 | 0.27 | 0.04 | -0.34 | -0.24 | 0.10 | 0.32 | 0.25 | 0.24 | -0.66 | 0.00 | -0.10 | -0.06 | 0.10 | 0.22 | 0.48 | 0.23 | 1.38 | 0.28 | -1.55 | 0.75 | - | 1.00 | 1.15 | 1.17 | 1.20 | 0.82 | 0.88 |
| R&D Expense | 6.50M | - | 7.03M | 8.09M | 8.13M | - | 8.01M | 8.19M | 9.09M | - | 11.67M | 13.46M | 13.73M | - | 12.95M | 22.73M | 34.92M | - | 18.08M | 17.74M | 16.73M | - | 20.56M | 19.56M | 21.32M | - | 19.99M | 21.54M | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 88.85M | 125.51M | 186.09M | 263.32M | 333.76M | 444.94M | 547.40M | 560.41M | - | 847.13M | 1.06B | 1.19B | 1.40B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | 311.93M | 375.88M | 439.62M | 461.23M |
| Gross Profit | 57.88M | 82.84M | 124.06M | 170.83M | 217.14M | 292.53M | 371.96M | 338.18M | - | 535.21M | 682.64M | 755.00M | 942.44M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 529.12M | 590.88M | 668.77M | 753.19M |
| Operating Income | -1.13M | 3.01M | 4.18M | -1.35M | 1.17M | -852.00K | 47.51M | -38.94M | - | 6.08M | 91.77M | 86.22M | 189.25M |
| EBITDA | - | - | - | - | - | - | - | - | - | 29.96M | 108.65M | 45.99M | 223.91M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 1.75M | 1.74M | 1.42M | 1.31M |
| Pretax Income | - | - | - | - | - | - | - | - | - | 3.89M | 79.65M | 20.87M | 205.12M |
| Tax Provision | - | - | - | - | - | - | - | - | - | 5.89M | -11.30M | 6.86M | 27.44M |
| Net Income | 4.10M | 2.25M | 2.37M | 14.81M | 4.66M | 6.60M | 48.46M | -15.70M | - | -2.00M | 90.95M | 14.01M | 177.69M |
| Diluted EPS | 0.14 | -0.18 | 0.08 | 0.44 | 0.13 | 0.18 | 1.34 | -0.44 | - | -0.05 | 2.32 | 0.36 | 4.52 |
| R&D Expense | 14.08M | 15.57M | 18.03M | 23.88M | 31.66M | 36.16M | - | - | - | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Jan 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 121.38M | 263.85M | 275.12M | 283.94M | 306.49M | 308.25M | 476.67M | 515.01M | 557.86M | 665.90M | 822.98M | - | 1.37B | 1.56B | 1.53B | 1.83B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 755.70M | 915.40M | 951.12M | 1.22B |
| Cash & Equivalents | 7.43M | 4.13M | 3.29M | 19.55M | - | - | - | 13.24M | 50.64M | 67.85M | - | 72.78M | 69.67M | - | 69.86M | 167.49M | 324.40M | 186.90M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 334.01M | 388.02M | 406.74M | 431.55M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 203.38M | 201.77M | 167.67M | 190.02M |
| Total Liabilities | - | - | 22.28M | 31.33M | 37.07M | 36.39M | 42.88M | 41.71M | 76.26M | 92.59M | 135.44M | 180.29M | 185.19M | - | 372.03M | 377.36M | 382.25M | 398.92M |
| Current Liabilities | - | - | 20.82M | 28.15M | - | - | - | 35.80M | 51.58M | 66.06M | 69.54M | 91.05M | 105.93M | - | 144.93M | 151.14M | 158.34M | 183.13M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 235.77M | 234.34M | 223.39M | 219.70M |
| Total Equity | -12.75M | -8.06M | -12.37M | 232.52M | 238.05M | 247.56M | 263.60M | 266.55M | 400.41M | 422.24M | - | 485.89M | 641.50M | - | 998.86M | 1.18B | 1.15B | 1.43B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 38.11M | 38.68M | 38.49M | 39.23M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.40M | -6.39M | -20.69M | -12.81M | 12.69M | 28.81M | 26.65M | -33.24M | - | -55.66M | 97.33M | 168.48M | 238.66M |
| Investing Cash Flow | -1.25M | -37.00M | -85.82M | 687.00K | -77.65M | -385.00K | -12.71M | -104.15M | - | 54.79M | -16.08M | 77.62M | -404.59M |
| Financing Cash Flow | 2.18M | 42.90M | 122.83M | 7.13M | 104.36M | -9.81M | -8.96M | 134.92M | - | 11.62M | 16.20M | -87.01M | 26.53M |
| Capital Expenditure | -798.00K | -3.89M | -5.47M | -13.63M | -12.53M | -9.60M | -22.11M | -24.76M | - | -19.30M | -15.21M | -21.18M | -63.73M |
| Free Cash Flow | -4.19M | -10.28M | -26.16M | -26.44M | 159.00K | 19.20M | 4.54M | -58.00M | - | -74.96M | 82.12M | 147.30M | 174.93M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | 10.75M | 97.46M | 159.10M | -139.40M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | 0 | 0 | 100.39M | 0 |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 65.1% | 66.0% | 66.7% | 64.9% | 65.1% | 65.7% | 68.0% | 60.3% | - | 63.2% | 64.5% | 63.2% | 67.1% |
| Operating Margin % | -1.3% | 2.4% | 2.2% | -0.5% | 0.3% | -0.2% | 8.7% | -6.9% | - | 0.7% | 8.7% | 7.2% | 13.5% |
| Net Margin % | 4.6% | 1.8% | 1.3% | 5.6% | 1.4% | 1.5% | 8.9% | -2.8% | - | -0.2% | 8.6% | 1.2% | 12.7% |
| ROE % | -50.8% | -18.1% | 1.0% | 5.6% | 1.2% | 1.6% | 10.0% | -2.4% | - | -0.2% | 7.7% | 1.2% | 12.4% |
| ROCE % | - | 3.0% | 1.8% | -0.5% | 0.3% | -0.2% | 8.3% | -5.4% | - | 0.5% | 6.5% | 6.3% | 11.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 10.91% | 4.30M | $1.36B |
| 2 | HBK Investments L P | 4.67% | 1.84M | $583.91M |
| 3 | Vanguard Capital Management LLC | 4.34% | 1.71M | $543.06M |
| 4 | Vanguard Portfolio Management LLC | 4.23% | 1.67M | $529.53M |
| 5 | State Street Corporation | 3.16% | 1.24M | $394.86M |
| 6 | ExodusPoint Capital Management, LP | 2.77% | 1.09M | $346.32M |
| 7 | Balyasny Asset Management LP | 2.77% | 1.09M | $346.24M |
| 8 | JPMORGAN CHASE & CO | 2.72% | 1.07M | $340.29M |
| 9 | Goldman Sachs Group Inc | 2.15% | 847.10K | $269.04M |
| 10 | Arrowstreet Capital, Limited Partnership | 2.12% | 834.90K | $265.17M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PEN
Penumbra Stock Price Forecast. Should You Buy PEN? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiR0FVX3lxTE5lLTJCazMwaEZ4RUc1UktFSVNEOWdLeG8wMGM1a0tReU56MlJYUTYwMURmV0QzRWJGOUpYU1lYU1BtUnhtTHdn?oc=5" target="_blank">Penumbra Stock Price Forecast. Should You Buy PEN?</a> <font…
TFX or PEN: Which Is the Better Value Stock Right Now? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxNWWlCamVhYmFUQkw0ZVN4VElYRER4QktUUzVZaUFWVTFXRG9Dc29KdXRqWlVXVThlWF91eFh5UUR0UUZNb01HbHY3OGdSZEE4V1dXZE9NZDloM04yUWFLZjBXVUREdXh5dDZ6ZGl5MTlYYlRQcXNqM241V0xMMEpTRHdxM0ljU3hvckdlUV…
Discipline and Rules-Based Execution in PEN Response - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQLWZTTHpIQmI5aXJRbUNKcUxsWE5Hcm9BRTV5TWd5ZTFjUlFsUWNVdW9YN2hRWXdubzBaNy15RFRfMURvbjNxODlOc3lnNVZ0TzlEMU5raWlGeG1YMmNGNXQxOUZnSVJUZlNLdndWUWl3NFBZUWY2al9uSzVTQTdneGtvLU13c2NLYWIzVX…
Penumbra, Inc. (PEN) Stock Analysis: Unraveling The 12.48% Potential Upside - directorstalkinterviews.com
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPNFg5SmN1eDJBZUViYXNWQXBGYjFuNXBDaXJLRmZWVk9WVnZqN1lnWm41bGxPSVR5cTh5a25ZZVYwcHdZZlV6Qjlhb0FzNGRBTkZGZGpNTFFUaUY2VzVPelA0QXZPLTlqTlFZQ2FXRHJRSFNNMi0zcklzeTUwT2RrVndreFFaWklIcWUtbG…
2 Reasons to Avoid PEN and 1 Stock to Buy Instead - StockStory
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxNZm9oZkNZX3IyVGN0UVlJamlMNlBEQ2Z6S0xrYmtsMHYyVkpLVnBsLWVmTjZzM2ZrOUJ0SGg0Q21FcXh6YUtHS0doTGZHZEFnb0dPSl9WOWlMSWllSGdjMC0xR3NIRmRXbTZEbHFZUDFPREplOVhYc2toSFhmWElOS0lPaWJzM0hIazdReG…
PEN - Penumbra Inc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiREFVX3lxTFB2b0VNbmJpdzVGWEZJNmkyell0NjR0MzFXRGlOZVRyVVZEaHJKdWlUcFpzRW1Wc2Y0M1NzLXp5c3hxQ09w?oc=5" target="_blank">PEN - Penumbra Inc Stock Price and Quote</a> <font color="#6f6f6…
PEN — Frequently Asked Questions
What is the current share price of Penumbra, Inc. (PEN)?
As of 2026-09-19 21:16 PDT, Penumbra, Inc. (PEN) trades at $319.26 on NYSE. Its 52-week range is $225.54 to $359.40.
What is the market capitalisation of PEN?
Penumbra, Inc. (PEN) has a market capitalisation of $12.58B on NYSE.
What is the P/E ratio of PEN?
PEN trades at a trailing price-to-earnings (P/E) ratio of 78.25. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 8.17.
What is the return on equity (ROE) of PEN?
PEN has a return on equity (ROE) of 11.37%. Its return on capital employed (ROCE) is 11.52%.
Is PEN a good stock to buy?
This page provides a data-driven analysis of Penumbra, Inc. (PEN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.